Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...